David Borges Sells 5,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $16.95, for a total transaction of $84,750.00. Following the completion of the sale, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at $84,750. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Performance

Shares of OMER opened at $17.19 on Wednesday. Omeros Corporation has a fifty-two week low of $3.94 and a fifty-two week high of $18.14. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of 13.43 and a beta of 2.54. The firm has a 50-day simple moving average of $11.18 and a 200-day simple moving average of $11.61.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. Equities research analysts forecast that Omeros Corporation will post -0.37 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on OMER shares. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research report on Saturday. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. D. Boral Capital reissued a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday, April 21st. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Omeros has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in OMER. UBS Group AG grew its stake in Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after acquiring an additional 1,513,893 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Omeros by 85.2% during the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock worth $1,897,000 after acquiring an additional 82,646 shares during the last quarter. Corient Private Wealth LLC raised its position in Omeros by 13.0% during the fourth quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock worth $11,817,000 after acquiring an additional 79,263 shares during the last quarter. AlphaQuest LLC raised its position in Omeros by 8,259,600.0% during the fourth quarter. AlphaQuest LLC now owns 82,597 shares of the biopharmaceutical company’s stock worth $1,419,000 after acquiring an additional 82,596 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Omeros by 19.9% in the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.